| Therapeutic | Rontalizumab |
| Target | IFNA1 |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK |
| 100% seqID Fv Structure | 4z5r [Fvs: BA, KJ, ML, QP, SR, UT, WV, ZY] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4z5r [Fvs: BA, KJ, ML, QP, SR, UT, WV, ZY] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Discontinued |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2009 |
| INN Year Recommended | 2010 |
| Companies Involved | Chugai Pharmaceutical, Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Systemic lupus erythematosus |
| Notes |
